EP0926955A4 - Conjugues utiles dans le traitement du cancer de la prostate - Google Patents

Conjugues utiles dans le traitement du cancer de la prostate

Info

Publication number
EP0926955A4
EP0926955A4 EP97942423A EP97942423A EP0926955A4 EP 0926955 A4 EP0926955 A4 EP 0926955A4 EP 97942423 A EP97942423 A EP 97942423A EP 97942423 A EP97942423 A EP 97942423A EP 0926955 A4 EP0926955 A4 EP 0926955A4
Authority
EP
European Patent Office
Prior art keywords
treatment
prostate cancer
conjugates useful
conjugates
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97942423A
Other languages
German (de)
English (en)
Other versions
EP0926955A1 (fr
Inventor
Dong-Mei Feng
Victor M Garsky
Raymond E Jones
Allen I Oliff
Jenny M Wai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9624170.8A external-priority patent/GB9624170D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0926955A1 publication Critical patent/EP0926955A1/fr
Publication of EP0926955A4 publication Critical patent/EP0926955A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97942423A 1996-09-12 1997-09-10 Conjugues utiles dans le traitement du cancer de la prostate Withdrawn EP0926955A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2601596P 1996-09-12 1996-09-12
US26015P 1996-09-12
GB9624170 1996-11-19
GBGB9624170.8A GB9624170D0 (en) 1996-11-19 1996-11-19 Conjugates useful in the treatment of prostate cancer
PCT/US1997/016087 WO1998010651A1 (fr) 1996-09-12 1997-09-10 Conjugues utiles dans le traitement du cancer de la prostate

Publications (2)

Publication Number Publication Date
EP0926955A1 EP0926955A1 (fr) 1999-07-07
EP0926955A4 true EP0926955A4 (fr) 2003-05-07

Family

ID=26310443

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97942423A Withdrawn EP0926955A4 (fr) 1996-09-12 1997-09-10 Conjugues utiles dans le traitement du cancer de la prostate

Country Status (5)

Country Link
EP (1) EP0926955A4 (fr)
JP (1) JP2001501601A (fr)
AU (1) AU715632B2 (fr)
CA (1) CA2265476A1 (fr)
WO (1) WO1998010651A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1181092C (zh) * 1997-12-02 2004-12-22 麦克公司 可用于治疗前列腺癌的缀合物
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE69942128D1 (de) * 1998-12-11 2010-04-22 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
US6649587B1 (en) * 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
AU1094601A (en) * 1999-10-19 2001-04-30 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE60020997T2 (de) * 1999-12-06 2006-05-24 Hopital Sainte-Justine, Montreal Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose
MXPA02009019A (es) 2000-03-15 2003-02-12 Du Pont Pharm Co Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico.
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
KR20040106547A (ko) 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
EP2517730A3 (fr) 2003-01-27 2013-01-02 Endocyte, Inc. Conjugués d'administration de médicaments à liaison au récepteur de vitamines
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8044200B2 (en) 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
EP1900742A1 (fr) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugues des disorazoles et leurs dérives avec des molécules de liaison cellulaire, nouveaux dérives de disorazole, leurs modes de préparation et utilisation
EP2481427A1 (fr) 2007-03-14 2012-08-01 Endocyte, Inc. Conjugués de folate et de tubulysine
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (fr) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysines et leurs procedes de preparation
WO2012123755A1 (fr) 2011-03-17 2012-09-20 The University Of Birmingham Immunothérapie redirigée
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
GB201402267D0 (en) * 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
CA2971288A1 (fr) 2015-02-02 2016-08-11 The University Of Birmingham Complexes d'epitope de peptide de fragment de ciblage ayant une pluralite d'epitopes de lymphocyte t
WO2017087789A1 (fr) 2015-11-19 2017-05-26 Revitope Limited Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0647450A1 (fr) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Prodrogues améliorées pour activation médiée par enzyme
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
EP0855910A4 (fr) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugues utiles pour traiter l'adenome prostatique benin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9810651A1 *

Also Published As

Publication number Publication date
CA2265476A1 (fr) 1998-03-19
EP0926955A1 (fr) 1999-07-07
AU715632B2 (en) 2000-02-03
AU4412397A (en) 1998-04-02
WO1998010651A1 (fr) 1998-03-19
JP2001501601A (ja) 2001-02-06

Similar Documents

Publication Publication Date Title
EP0926955A4 (fr) Conjugues utiles dans le traitement du cancer de la prostate
IL129356A0 (en) Conjugates useful in the treatment of prostate cancer
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
EP0855910A4 (fr) Conjugues utiles pour traiter l'adenome prostatique benin
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
GB9703633D0 (en) Cancer therapy
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
GB9626309D0 (en) Conjugates useful in the treatment of prostate cancer
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
GB9718160D0 (en) Conjugates useful in the treatment of prostate cancer
GB9810183D0 (en) Conjugates useful in the treatment of prostate cancer
GB9815855D0 (en) Conjugates useful in the treatment of prostate cancer
GB9804399D0 (en) Conjugates useful in the treatment of prostate cancer
GB9804361D0 (en) Cancer treatment
HK1034979A1 (en) Conjugates useful in the treatment of prostate cancer.
EP0871709A4 (fr) Lignee cellulaire du cancer de la prostate a metastases, chez l'homme, ayant regresse sous l'influence d'un androgene
GB9903035D0 (en) Treating cancer
GB2334579B (en) Treating cancer
GB9617941D0 (en) New approach to the treatment of prostate cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990412

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030320

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/16 B

Ipc: 7A 61K 38/28 B

Ipc: 7A 61K 38/00 B

Ipc: 7A 01N 37/18 B

Ipc: 7A 61K 47/48 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040121